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A.D. Anno Domini (Latin, in the year of our lourd). 
AF. Atrial fibrillation. 
ATRIA. Anticoagulation and Risk Factors in Atrial Fibrillation. 
B.C. Before Christ. 
CKD. Chronic kidney disease. 
CKD-EPI.  The Chronic Kidney Disease Epidemiology Collaboration. 
ECG. Electrocardiogram. 
eGFR. Estimated glomerular filtration rate. 
GFR. Glomerular filtration rate 
ICH. Intracranial hemorrhage.  
INR. International normalized ratio. 
MDRD-4. The 4-variable Modification of Diet in Renal Disease. 
NOACs. New oral anticoagulants. 
NVAF. Non-valvular atrial fibrillation. 
PINRR. Proportion of  international normalized ratios in range. 
RR. Relative risk. 
TE. Thromboembolic. 
TIA. Transient ischemic attack. 
TTR. Time within therapeutic range. 
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Atrial Fibrillation (AF) is known to be the most commonly sustained cardiac rhythm 
disorder, and is considered a major cause of health care expenditure. Despite that AF is 
usually not a life-threatening arrhythmia, it affects the quality of life significantly 
mainly as a result of its anatomic, hemodynamic, and thromboembolic (TE) 
consequences. This means that AF is associated with very important socioeconomic 
problems, such as permanent disability, cognitive disturbance, hospitalization, and 
absence from work. 
 
Assessing the risk of poor anticoagulation control in patients with non-valvular atrial 
fibrillation recently on vitamin K antagonists:  
 
Among the negative effects and consequences of AF, it is known that AF increases the 
risk of embolic stroke by five fold. Furthermore, stroke in AF is associated with greater 
mortality and morbidity, with more disability and longer hospital stays compared to 
stroke event in patient without AF.  Vitamin K antagonists (VKAs) are still the most 
used oral anticoagulants in patients with non-valvular atrial fibrillation (NVAF) and are 
highly effective for the prevention of TE complications in these patients. However, 
achieving the best benefit and safety from VKAs in the clinical practice remains a major 
challenge mainly because of their unpredictable anticoagulant response. Several reports 
indicate a strong relation between poor quality of international normalized ratio (INR) 
control and the increased rates of both stroke and major hemorrhage in patients on 
VKAs. Various large cohort studies demonstrate that the level of the quality of INR 
control in real life practice is still below the optimal level of time within therapeutic 




It is well known that previous long term records of INR values are the best estimate of 
anticoagulation control in patients who are on VKAs for a long time. However, for 
VKAs naïve patients or patients who are recently on VKAs, there is substantial interest 
to find a tool that can predict how they will do with VKAs at intermediate and long term 
in real life practice. Moreover, with the availability of new oral anticoagulants 
(NOACs), the landscape of anticoagulation management in NVAF has been 
revolutionized as these new drugs are considered safer than VKAs. It is now clear that 
there is a strong need to characterize VKAs naïve AF patients who are at risk of having 
poor INR control as these patients would need more follow-up visits or they will be 
suitable candidates for NOACs in order to avoid poor INR control-related complications 
such as thromboembolism and major bleeding. Fortunately, a quantitative clinical score 
(i.e. SAMe-TT2R2) was recently conceived to help clinicians in identifying patients who 
can do well on VKAs. However, the derivation and the internal validation cohorts of the 
SAMe-TT2R2 score were derived from a clinical trial which was not designed to assess 
the quality control of anticoagulation and as the SAMe-TT2R2 takes into account the 
race of patients as an important factor to predict the quality of INR control. These facts 
increase the need to test the SAMe-TT2R2 predictability in real life Galician patients 
with NVAF recently (i.e. for a better assessment of the SAMe-TT2R2 score) on VKAs. 
Moreover, there are strong arguments to investigate the effects of other comorbidities 
like cardiovascular diseases and renal dysfunction which usually accompany AF and 






A continuous need to evaluate current thromboembolic and bleeding risk scores and 
to define new risk factors in real life patients with non-valvular atrial fibrillation:  
 
Really, there has always been a strong motivation to improve the decision making 
process and the management plan in patients with NVAF, so there is a continuous need 
to evaluate current TE and bleeding risk scores and to define new risk factors. 
Clinicians increasingly appreciate that TE risk in AF patients is not homogeneous and is 
altered by the presence of certain risk factors. For instance, AF may coexist with 
systemic hypertension, heart failure and/or coronary artery disease which may influence 
both the approach to management and the treatment options, since the presence of these 
risk factors adds to AF-related TE complications, so the coexistence of the prior risk 
factors is an indication for anticoagulation.  
Different TE risk scores have been developed to help clinicians in the decision making 
process regarding the prescription of oral anticoagulants for AF patients in order to 
reduce the risk of the catastrophic TE event. However different critical points are still 
on our minds as cardiologists and/or clinical investigators.  
The burden of major bleeding is the downside of the anticoagulation treatment as the 
incidence of intracranial bleeding with VKAs ranges from 0.3 to 1.8%.  Moreover, 
different TE risk factors like age, hypertension and prior cerebrovascular event were 
also found to be bleeding risk predictors. This makes prescribing oral anticoagulants to 
AF patients a very difficult decision. Furthermore, a sizeable subgroup of AF patients 
still has a significant risk of developing TE events despite being on anticoagulation. So, 
there is great interest to evaluate this risk and how the current TE risk scores can help us 
to characterize this subgroup of patients as this particular subpopulation might need 
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different management strategies and closer follow up in order to improve the prognosis 
of these patients.   
The estimate that the risk of major adverse event (i.e. TE event and major bleeding) is 
highest in the first few months after initiation of VKAs, may point to the importance of 
risk assessment for those patients who are recently started on VKAs. 
Several scoring systems are available to estimate TE and bleeding risk in AF patients. 
However, more arguments still need further investigations as many of the validation 
studies for these scores were not done on real life cohorts and this raises some doubts 
about their performance in AF patients from the real world.  Moreover, given the 
differences in patient characteristics and medical assistance (i.e. different health 
systems) resulting from geographic location, when a predictive model or risk score is to 
be used outside the environment in which it was created, it first needs to be validated for 
its new context; only then can users be sure that the scores provided are not misleading. 
Currently, there is limited data on the usefulness of contemporary risk scores 












Renal dysfunction and adverse events in anticoagulated patients with non-valvular 
atrial fibrillation: 
 
 In the dilemma of oral anticoagulation for patients with NVAF there is a specific issue 
of great concern which is the current controversy about the role of renal dysfunction — 
a frequent comorbidity observed in patients with AF— on the quality control of oral 
anticoagulation and outcomes. Patients with AF and renal dysfunction are more likely to 
develop TE events compared to those individuals with AF but without renal 
dysfunction. On the other hand, the presence of renal dysfunction is also a recognized 
predictor in the bleeding risk scores used commonly to estimate the hemorrhagic risk 
(i.e. HAS-BLED and ATRIA [Anticoagulation and Risk Factors in Atrial Fibrillation] 
scores). In addition, patients with NVAF are often elderly with multiple comorbidities 
which require pharmacotherapy of increasing complexity. All these factors make the 
accurate assessment of renal function to be of great importance as it will help inform the 
decision making process aiming to improve the management of patients with AF.  
There are various equations used to calculate the estimated glomerular filtration rate 
(eGFR) and nowadays the two most commonly used equations are the re-expressed 4-
variable Modification of Diet in Renal Disease (MDRD-4), and the new Chronic 
Kidney Disease Epidemiology Collaboration (CKD-EPI) equation which is currently 
considered more accurate than the re-expressed MDRD-4. However, until now there is 
little information about the derived reliability from both equations in the specific area of 








Although the general and specific objectives proposed for each of the analyzed topics 
are detailed in different chapters of the thesis, they can be summarized as follows: 
 
1- To evaluate the quality of oral anticoagulation in a real world cohort of patients with 
NVAF recently on VKAs. In this regard we aimed to assess the ability of the new 
SAMe-TT2R2 risk score at predicting different levels of anticoagulation control in a real 
world cohort of patients with NVAF recently (i.e. for a better assessment of SAMe-
TT2R2 score) on VKAs. We also have specific objectives to examine the relation of 
SAMe-TT2R2 score with major bleeding, TE complications, and all-cause mortality; 
either as a composite outcome or as individual events. Additionally, we aimed to 
investigate some of the cardiovascular and cardinal variables that have a widely held 
belief as strong predictors of poor anticoagulation control. 
2- To carry out a comparative validation of three contemporary risk scores for 
predicting TE event in patients with NVAF. In this regard we aimed to evaluate the 
ability of CHA2DS2-VASc, R2CHADS2, and new ATRIA scores at predicting TE events 
in two different real life cohorts of non-anticoagulated and anticoagulated patients with 
NVAF which have full spectrum of eGFR. 
 
3- To perform a comparative validation of HAS-BLED versus ATRIA by investigating 
the full potential of the two bleeding prediction schemes as they were originally 
conceived, in a real life cohort of patients with NVAF recently on VKAs and to identify 
other comorbidities that would be associated with major bleeding beyond those already 
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included in HAS-BLED and ATRIA scores. We also interested to test the association 
between poor quality of INR control (i.e. labile INR) and major bleeding event. 
 
4- To investigate the relation between renal dysfunction and adverse outcomes (i.e. poor 
quality control of VKAs, TE event, major bleeding and mortality) in a real life cohort of 
patients with NVAF who are on VKAs. We also aimed to comparatively assess the 
glomerular filtration rate (GFR) estimating formulas namely the re-expressed MDRD-4 
and the new CKD-EPI formulas at identifying patients with renal dysfunction, and at 
predicting the occurrence of major adverse outcomes in a real world cohort of patients 












































Historical review of atrial fibrillation: 
 
Physicians have been fascinated by patient's pulses for over centuries. The worst 
prognosis associated with the irregularity of cardiac rhythm was noted and described by 
the ancient physicians. Hippocrates [around 460 - 370 Before Christ (B.C)] described a 
clinical case of a patient with poor prognosis and violent palpitation of the heart and 
stated in his aphorisms: "Those who are subject to frequent and severe fainting attacks 
without obvious cause die suddenly" [1]. However, that palpitation could be due to 
another arrhythmia. Later on, in 1187 Anno Domini (A.D), Moses Maimonides wrote 
aphorisms that pertained to the human pulse. He described in some of his manuscripts a 
totally irregular pulse that was most likely atrial fibrillation [2]. 
 
Figure 1.1: Hippocrates around 460 - 370 B.C. 
In 1876 A.D, when Carl Wilhelm Hermann Nothnagel, was the first to record the pulse 
waves in AF, and he observed that "In this form of arrhythmia the heart beats follow 
each other in complete irregularity. At the same time, the height and tension of the pulse 
waves are continuously changing" [3]. Following the first record of the pulse wave in 
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AF, James Mackenzie in 1904 A.D, observed that the atrial pulse waves, measured in 
jugular veins, disappeared at the onset of the persistent irregular arterial pulse and 
returned when the pulse became regular again [4]. Thereafter, there was a general 
consensus that the three essential features of “the absolutely irregular heart” were an 
absolute irregularity of the arterial pulse, the persistence of the abnormal rhythm and the 
absence of venous atrial pulse waves [3,5]. It is well recognized now that the 
development of the electrocardiogram (ECG) by Einthoven and the studies which have 
been done by him and Sir Thomas Lewis clearly put atrial fibrillation on the map. 
Willem Einthoven, published the first ECG in a human being, showing AF in 1906 A.D, 
without having clear idea about its true nature [6]. Electrocardiographic studies in 1910 
A.D, which were done by Thomas Lewis, highlighted that the fine oscillations between 
the R waves, which were thought to be disturbances, were evidence of atrial activity 
throughout the cardiac cycle [7]. Using the chest leads, Lewis demonstrated that these 
oscillations originated from the atria rather than from the atrioventricular node, and 
noticed that the R wave had its normal electrical vector during the irregular pulse and he 
concluded that the ventricular activity must therefore start from its usual point [3]. 
Thomas Lewis, had the chance to test and to observe the phenomenon of heart 
irregularity in horses, where he saw the auricles of the atria trembling, when  ECG 
findings and venous pressure curves were consistent with AF, and he named this 




Figure 1.2: The first atrial fibrillation recorded by ECG in 1906 by Willem Einthoven 
[6]. 
Current definition of atrial fibrillation: 
 
AF is defined as a cardiac arrhythmia with the following characteristics [8]: 
(1) The surface ECG shows ‘absolutely’ irregular RR intervals (AF is therefore 
sometimes known as arrhythmia absoluta), i.e., RR intervals which do not follow a 
repetitive pattern. 
(2) There are no distinct P waves on the surface ECG. Some apparently regular atrial 
electrical activity may be seen in some ECG leads, most often in lead V1. 
(3) The atrial cycle length (when visible), i.e. the interval between two atrial activations, 
is usually variable and <200 milliseconds (>300 beat per minute). 
It is conventional to divide AF into cases which are described as “valvular or non-
valvular” as the natural history and management of both types of AF is different. 
NVAF is defined as AF in the absence of rheumatic mitral stenosis, a mechanical or 






Mechanism and thrombogenesity of atrial fibrillation: 
 
Structural heart disease like heart failure, coronary artery disease or hypertension may 
induce progressive structural remodeling in both the ventricles and the atria. In the atria, 
proliferation and differentiation of fibroblasts into myofibroblasts with enhanced 
connective tissue deposition and fibrosis are the hallmarks of this process [10]. 
Structural remodeling leads to electrical remodeling which results in electrical 
dissociation between muscle bundles and local conduction heterogeneities facilitating 
the initiation and perpetuation of AF [10]. This electro-anatomical substrate allows 
multiple small re-entrant circuits that can stabilize AF. There are three types of atrial 
remodeling: structural, contractile and electrical. They are related to each other and 
contribute to maintaining the AF [11]. Factors affecting hemodynamic function in 
patients with AF involve loss of coordinated atrial contraction, rapid ventricular rates, 
irregularity of the ventricular response, and decrease in myocardial blood flow, as well 
as long term changes such as atrial and ventricular cardiomyopathy [10,11]. Acute loss 
of coordinated atrial mechanical function during an episode of AF reduces cardiac 
output by 5–15% [11]. This effect is more pronounced in patients with already reduced 
ventricular compliance in whom atrial contraction contributes significantly to 
ventricular filling. High ventricular rates limit ventricular filling due to the short 
diastolic interval. Rate-related interventricular or intraventricular conduction delay may 
lead to non-synchronization of the left ventricle and further reduction of cardiac output. 
In addition, irregularity of the ventricular rate can reduce cardiac output [11]. Because 
of force–interval relationships, persistent variations of the RR intervals cause significant 
variability in the strengths of subsequent heart beats, so resulting in pulse deficit. 
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Sustained elevation of ventricular rates above 130 bpm may produce ventricular 
tachycardiomyopathy [12].  
TE risk associated with AF is linked to a number of underlying pathophysiological 
mechanisms which fulfill the Virchow triad of thrombogenesis. ‘Flow abnormalities’ in 
AF are evidenced by stasis within the left atrium, with reduced left atrial appendage 
flow velocities, and visualized as spontaneous echo-contrast on transoesophageal 
echocardiography [13]. Endocardial abnormalities include progressive atrial dilatation, 
endocardial denudation, and edematous/fibro-elastic infiltration of the extracellular 
matrix. The left atrial appendage is the dominant source of embolism (90%) in NVAF. 
Abnormalities of blood constituents are well described in AF and include haemostatic 
and platelet activation, as well as inflammation and growth factor abnormalities [13].  
An autopsy study in patients with history of strokes demonstrated the presence of 
significant intracardiac thrombus in 20% of patients with atrial fibrillation [14]. Another 
autopsy study showed that about two thirds of patients with long-term AF had a 
thrombus in their left atrial appendage [15]. 
The dissociation of a part of the thrombus from the left atrial appendage can lead to the 
most feared complication in AF, ischemic stroke. The risk of stroke is increased fivefold 
in the presence of AF, and it is estimated that in one out of every four strokes, AF is the 
source of thromboembolism [16].  
A meta-analysis of different trials has demonstrated an average annual stroke rate of 
4.5% for patients without a previous stroke and 12% for patients with a previous history 
of stroke in those patients not receiving antithrombotic therapy [17]. It is clear that the 





Figure 1.3: Atrial fibrillation and the risk of thromboembolic stroke. Source: National 
Heart, Lung, and Blood Institute, United States of America. 
 
Prevalence and burden of atrial fibrillation “magnitude of the problem”: 
 
In the last 20 years, AF has become one of the most important public health issues and 
an important cause of health care expenditure in western countries. AF influences 
quality of life significantly as a result of its anatomic, hemodynamic, and 
hemocoagulative consequences. In addition, AF is frequently associated with disturbing 
symptoms and critical socioeconomic problems, such as permanent disability, cognitive 
disturbance, hospitalization, and absence from work [18]. 
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The most common and reliable studies on the epidemiology of AF which were carried 
out in developed countries and published between the end of the 20th century and the 
first years of the 21st century estimated the prevalence of AF to be between 0.5% and 
1% in the general population [19,20].  However, in the last decade, and as perceived by 
the number of hospitalizations, emergency room visits, and burden of outpatient visits 
for AF, the common opinion was that the prevalence of AF had to be markedly higher 
[20-22]. The most recent studies have confirmed this perception and demonstrated that 
the prevalence of AF in the general adult population of Europe is more than double that 
reported just one decade earlier, it is now ranging from 1.9% in Italy, Iceland, and 
England to 2.3% in Germany and 2.9% in Sweden [23].  
In the United States of America, it appears that the prevalence of AF has increased by 
0.3% per year in Medicare beneficiaries older than 65 years, with a real growth of 4.5% 
(from 4.1% to 8.6%) in the period 1993-2007[24-29]. However, despite this increase, 
the actual prevalence of AF is probably still underestimated because it is well known 
that AF, in a discrete proportion (10%–25%) of cases, occurs in the absence of 
symptoms [30,31]. In this regard, even if AF was detected appropriately by active 
screening, its true prevalence would be higher and closer to 3%, as estimated for 2015 
in the United States of America [30-32]. In developing countries, AF occurs in 
approximately 0.6% of males and 0.4% of females. Although these rates are markedly 
lower than in developed nations, it appears that the burden of AF in these countries is 
enough to be a potential problem for health care systems [33].  
In Spain, a recent study demonstrated that the prevalence of AF in the general Spanish 
population older than 40 years is high, at 4.4%. Actually, it is estimated that there are 
more than one million patients with AF in the Spanish population [34]. Another study 
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was held in Spain and showed that the prevalence of AF has progressively increased 
with age and reached 6.3% for those older than 75 years [35].   
At the present time, in the European Union (estimated population of 500 million people) 
there are approximately 10 million patients with AF and 100,000–200,000 with new-
onset AF. In the year 2030 the prevalence of AF would be 2.7%–3.3% in a European 
population with 516–525 million inhabitants. Therefore, within 15 years, the number of 
European citizens with AF will be 14-17 million and the number of new AF cases will 
be 120,000–215,000 per year [23]. There will be approximately 14 million AF patients 
among individuals aged >55 years in the year 2030 [36]. To these figures must be added 
a further 280,000–340,000 new ischemic strokes, 3.5-4 million hospitalizations for AF, 
and 100–120 million outpatient visits [23]. The magnitude of this data seems to confer 
an endemic dimension to this health care problem, implying not only a greater 
engagement of physicians but also a significant effort of health care systems to improve 
AF prevention and treatment and to facilitate the organization of social interventions for 
the cure of its consequences [23,36]. 
The socioeconomic burden of AF in Spain and the European Union countries is 
considerable [37]. A study analyzing the costs of AF in five European countries showed 
that AF was associated with average healthcare costs from 1010 euros per patient per 
year in Poland up to 3225 euros per patient per year in Italy, while in Spain the average 
health care cost was about 2315 euros per patient per year [38]. The total annual costs 
for treating AF range from 272 million euros in Greece up to 3286 million euros in 




Figure 1.4: Demonstrates the significant burden of atrial fibrillation in term of high 
stroke risk [16]. NVAF: non-valvular atrial fibrillation. 
 
Atrial fibrillation in the context of cardiovascular disease: 
 
AF commonly coexists with cardiovascular disease and if inappropriately treated, the 
presence of these factors adds to the development of new onset AF [39], and to the 
complications associated with AF, such as stroke [40]. 
Systemic arterial hypertension: 
Hypertension is the most prevalent, independent, and potentially modifiable risk for 
atrial fibrillation [41,42]. In addition to its role as a major risk factor for the 
development of atrial fibrillation, the presence of hypertension increases the risk of 
stroke in patients with AF. Patients with AF have a 3 to 6 fold increase in stroke risk 
compared with the general population [16,43,44]. In patients with AF, hypertension 
worsens stroke rate by an additional 2 to 3 fold [45]. 
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The prevalence of systemic arterial hypertension in patients with AF was estimated to 
be about 76% in Spain [34]. In a prospective study which was carried out in Galician 
patients with AF demonstrated that hypertension was the most prevalent risk factor 
(77%) [46]. 
Heart failure: 
In Spain, a recent study demonstrated that heart failure is a common comorbidity among 
patients with AF with estimated prevalence of 29.4% [34]. The prevalence of heart 
failure in a registry of Galician patients with AF was 12.2% [46]. Recently, AF and 
heart failure have been recognized as the two epidemics of modern cardiovascular 
medicine [47]. Both conditions frequently coexist because heart failure is a strong risk 
factor for AF. The risk of AF increases 4.5 to 5.9 fold in presence of heart failure. AF 
prevalence increases as heart failure severity worsens. AF has been estimated to occur 
in 5% to 10% of patients with mild heart failure, 10% to 26% with moderate disease, 
and up to 50% with advanced heart failure [48-50]. Heart failure can be both a 
consequence of AF due to tachycardiomyopathy or decompensation in acute onset of 
uncontrolled AF and can be a cause of AF due to increased atrial pressure, volume 
overload and secondary valvular dysfunction with atrial dilatation or chronic 
neurohumoral stimulation [51,52]. An analysis of prospective registry of Galician 
patients with AF showed that 30.5% of AF patients with heart failure died during a 
mean follow up of 2.9 years compared to 14.4% of those with AF but without heart 
failure [53]. 
Coronary artery disease: 
After acute myocardial infarction, development of AF is associated with a worse 
prognosis [54]. Coronary artery disease is common among patients with AF and may be 
one of its underlying etiologies [55]. Moreover, AF may be the sole manifestation of 
27 
 
coronary artery disease [56]. Furthermore, epidemiological data has indicated that 
ischemic heart disease is one of the most common underlying causes of death among 
patients with AF [57].  
Once AF is diagnosed, the presence of coronary artery disease  is shown to be related to 
recurrent AF episodes [58], to the presence of symptoms (including arrhythmia, heart 
failure, and angina symptoms), and to increased risk of death [59,60]. Therefore, 
coronary artery disease plays an important role in the mortality and quality of life of 
patients with AF. 
It is estimated that about 17.9% of Spanish patients with AF have coronary artery 
disease [34]. A prospective registry of Galician patients with AF demonstrated that 
17.7% of them had ischemic heart disease which was an independent risk factor for 
mortality in these patients [46]. 
 
Vitamin K antagonists in atrial fibrillation: 
 
There is an extensive evidence base for the use of VKAs in AF, as this evidence has 
come from many randomized studies which demonstrated and proved the absolute 
benefit of VKAs in AF. 
Anticoagulation therapy with VKAs versus control: 
Between 1989 and 1993, six trials were published, five of them were large randomized 
trials evaluated VKAs mainly for the primary prevention of TE event in patients with 
NVAF [61-65]. The sixth trial focused on secondary prevention among patients who 
had survived non-disabling stroke or transient ischemic attack (TIA) [66]. In a large 
meta-analysis, the relative risk (RR) reduction with VKAs was highly significant and 
amounted to 64%, corresponding to an absolute annual risk reduction in all strokes of 
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2.7% [17]. When only ischemic strokes were considered, adjusted-dose VKAs use was 
associated with a 67% RR reduction. This reduction was similar for both primary and 
secondary prevention and for both disabling and non-disabling strokes.  Of note, all-
cause mortality was significantly reduced (26%) by adjusted-dose VKAs versus control 
[17]. 
VKAs versus antiplatelet therapy:   
The Birmingham Atrial Fibrillation Treatment of the Aged (BAFTA) study 
demonstrated that VKAs with INR in the therapeutic range of 2-3 were superior to 
aspirin 75 mg daily in reducing the primary endpoint of stroke, intracranial hemorrhage 
(ICH), or significant arterial embolism by 52%, with no difference in the risk of major 
hemorrhage between VKAs and aspirin [67].  Similar results were found in the small 
Warfarin versus Aspirin for Stroke Prevention in Octogenarians with AF (WASPO) 
trial, in which there were significantly more adverse events with aspirin (33%) than 
with warfarin (6%, p =0.002), including serious bleeding. When the trials conducted 
prior to BAFTA were considered, the risk for ICH was doubled with adjusted dose 
warfarin compared with aspirin, although the absolute risk increase was small (0.2% per 
year) [17]. 
In the Atrial fibrillation Clopidogrel Trial with Irbesartan for prevention of Vascular 
Events–Warfarin arm (ACTIVE W) trial, anticoagulation therapy was superior to the 
combination of clopidogrel plus aspirin (RR reduction 40%; 95% CI 18–56), with no 
difference in bleeding events between treatment arms [68]. The Aspirin arm (ACTIVE 
A) trial found that major vascular events were reduced in patients receiving aspirin–
clopidogrel, compared with aspirin monotherapy (RR 0.89; 95% CI 0.81–0.98; p 
=0.01), primarily due to a 28% relative reduction in the rate of stroke with combination 
therapy [69]. Major bleeding was significantly increased with combined aspirin-
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clopidogrel therapy (2.0% per year vs. 1.3% per year; RR 1.57; 95% CI 1.29–1.92; 
p=0.001), broadly similar to that seen with VKAs therapy. Of note, 50% of patients had 
entered the trial due to ‘physician’s perception of being unsuitable for VKAs therapy’ 
and 23% had a risk factor for bleeding at trial entry. Thus, double antiaggregant therapy 
with aspirin plus clopidogrel might be considered as an interim measure where VKAs 
therapy is unsuitable, but not as an alternative to VKAs in patients at high bleeding risk. 
INR as an index of quality control of anticoagulation with VKAs: 
The effects of VKAs on blood coagulation are measured by the INR using a 
prothrombin test [70]. INR is derived from the ratio between the actual prothrombin 
time and that of a standardized control serum and it is the world-wide standardized 
coagulation method used for monitoring and evaluating the effect of VKAs therapies 
[8]. To obtain optimal benefits of anticoagulation control, patients on treatment with 
VKAs therapy need to be maintained within their INR target/reference range, which 
requires regular monitoring and appropriate adjustment of treatment. To achieve a 
balance between embolic stroke risk with low INRs and an increasing bleeding risk with 
high INRs, an INR of 2.0–3.0 is the likely optimal range for prevention of stroke and 
systemic embolism in patients with NVAF on VKAs [8,18]. 
The efficacy and safety of VKAs therapy are closely associated to the quality of oral 
anticoagulation management [71,72]. The quality of anticoagulation can be measured by 
a number of methods and no standardized consensus exists as to which is the best 
measure, and as such, all of the available methods have specific advantages and 
disadvantages. Meta-analysis of 47 studies of patients with atrial fibrillation on oral 
anticoagulation treatment with VKAs demonstrated that TTR  measured by the 
Rosendaal method  and the PINRR were the most frequently reported measures to 
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determine the therapeutic effectiveness of oral anticoagulation proved that both method 
have a significant correlation  (r = 0.99, p= 0.001) [73]. 
Several studies have shown how a high TTR translates into a lower risk of stroke and 
bleeding, whilst on VKAs [73-76]. A recent European consensus document 
recommends that an average individual TTR should be > 70 % for optimal efficacy and 
safety outcomes whilst on VKAs and this is also recommended in the European 
Guidelines [77]. 
 
Figure 1.5: Keeping the INR in the therapeutic window reduces the adverse event. INR: 






Risk stratification in atrial fibrillation. A general overview: 
 
The increasing prevalence of AF brings a high burden of its related complications, 
among which major TE event like ischemic stroke is the most disabling and associated 
with high mortality and morbidity [78,79]. Stroke prevention is necessary in the 
management of patients with AF. Really, appropriate TE prophylaxis essentially 
requires oral anticoagulants [77]. However, anticoagulant agents used for TE event 
prevention in AF will potentially increase the risk of minor, major and fatal bleeding 
events. The incidence of ICH and fatal bleeding with VKAs ranges from 0.3 to 1.8% 
and from 0.5 to 1.0%, respectively [80]. Among patients treated with VKAs, the risk of 
severe disability or death occurs in only 3% of patients with major extracranial 
hemorrhage whereas it can be as high as 76% in patients with ICH [81]. The quality 
control of oral anticoagulation is the most important risk factor for bleeding and ICH. It 
has been demonstrated that the risk of major bleeding is nearly two-times higher in 
patients with INR >3.0 compared with patients with INR between 2 and 3 [82]. 
The understanding of the risks and benefits of oral anticoagulation therapy is of great 
value in the real world clinical practice [77,83]. Although AF increases stroke risk 5-
fold, this risk is not homogeneous. In a large cohort study of AF patients and over 6 
years of follow up, the annual rate of TE event was 1.09 per 100 person-years in 
patients with no history of stroke and 3.46 per 100 person-years in patients with a 
history of stroke, both receiving VKAs, and in turn, this means that there are still groups 
of AF patients having high TE risk despite anticoagulation. However, there were 0.51 
annual rates of ICH associated with VKAs therapy in patients with no history of stroke 
compared with 1.16 in patients with prior stroke [84]. 
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Many TE risk factors also confer an increased risk of bleeding. Various TE and 
bleeding risk-stratification schemes have been developed to help inform clinical 
decision-making. These scores were derived and validated in different study cohorts, 
ranging from highly selected clinical-trial cohorts to real-world populations. Thus, the 
performance and classification accuracy of these scores vary depending on their 
derivation cohort(s) [85]. 
 
 
Figure 1.6: The risk of stroke or bleeding is not homogenous and the assessment is 








Thromboembolic risk stratification in non-valvular atrial fibrillation: 
 
Many TE risk factors have been identified among AF patients and the patient’s risk will 
depend mainly on the combination of those risk factors, rather than from simply being 
an AF patient. Permutations of those risk factors have been used to design stroke risk-
stratification schemes, with the initial objective of identifying high-risk patients to be 
targeted for oral anticoagulant [86,87]. The derivation of stroke risk-stratification 
schemes depends on identification of common risk factors, which already have been 
defined and recorded in the derivation cohort [88].  
The CHADS2 score with the acronym (Congestive heart failure, Hypertension, Age ≥75 
years, Diabetes mellitus and prior Stroke or TIA) is one of the simplest and commonly 
used TE risk-stratification schemes. CHADS2 score is a point system in which 2 points 
are assigned to a history of prior cerebral ischemia and 1 point is assigned for the 
presence of each of the cardiac failure, hypertension, age ≥75 years, diabetes mellitus 
with a maximum score of 6 points [89]. 
It is well recognized that the CHADS2 score does well at identifying high-risk patients 
but provides less reliable results in those at low or moderate stroke risk [90]. 
Furthermore, the CHADS2 score has been subject to more criticism as it did not include 
important independent TE risk factors and because of the discrepancy observed between 
the original validation and further applications in guidelines and real-life cohorts [91].  
To overcome some of the limitations of the CHADS2 score, the CHA2DS2-VASc score 
has been proposed giving extra weight to age ≥75 years, as this is a major driver of 
stroke risk, and including additional risk factors such as age 65 to 74 years, female sex, 
and vascular disease. CHA2DS2-VASc is calculated by adding 2 points for Age ≥ 75 
years; 2 points for prior Stroke or TIA; and 1 point for each of the following factors: 
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Congestive heart failure\left ventricular ejection fraction ≤40%, Hypertension, Diabetes 
mellitus, Vascular disease [i.e. coronary artery disease, peripheral arterial disease or 
aortic plaque], Age 65 to 74 and Female Sex, with a maximum score of 9 points [92].  
CHA2DS2-VASc has been found to be superior to CHADS2 in numerous validation 
studies for identifying truly low-risk patients and in minimizing the categorization of 
patients as moderate risk [92-94].  
In a community based cohort of non-anticoagulated Galician patients with AF, 
CHA2DS2-VASc correctly identified the greatest proportion of AF patients at high risk 
[95].  
The current consensus has now shifted the focus from identifying ‘high-risk’ patients to 
identifying those patients who are truly at low risk using the CHA2DS2-VASc score. 
Although the current clinical practice guidelines recommend the use of CHADS2 and 
CHA2DS2-VASc risk scores in the effective TE prevention strategy [77,96,97]. 
However, in several studies, CHADS2 and CHA2DS2-VASc showed just a moderate 
discrimination ability to predict TE event [98,99], and in a recently published large 
cohort study, the annual ischemic stroke rate was noticeable in the group of patients 
classified in "the true low risk category" according to CHA2DS2-VASc [100].  
Furthermore, there is great interest in estimating the prognosis of patients who have a 
level of risk outside the CHA2DS2-VASc (i.e. those with renal dysfunction). All this 
could lead to a number of questions and potential avenues for further research. 
Recently, and with the aim to improve the ability to predict TE event, two new TE risk 
scores (i.e. R2CHADS2 [101] and the new ATRIA risk scores [102]) have demonstrated, 
in their own derivation cohorts, better performance than CHADS2 and CHA2DS2-VASc. 
Really, the two recently proposed risk scores contain new risk factors (e.g. renal 
dysfunction) in their schemes which were not included in the most recommended 
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CHA2DS2-VASc score. This fact could qualify them to strongly capture the risk of 
suffering a future TE event, but little information is available in this regard in 
independent dataset of patients with NVAF. R2CHADS2 is calculated by adding 2 
points for Renal dysfunction (i.e. creatinine clearance <60 mL/min); 2 points for prior 
Stroke or TIA; and one point for each of the following factors: Congestive heart failure, 
Hypertension, Age ≥ 75 and Diabetes mellitus with a maximum score of 8 points [101]. 
Really, the development of the R2CHADS2 score was driven by the knowledge that AF 
and kidney dysfunction coexist commonly and both increase the risk of stroke. 
Although, the R2CHADS2 score might have some limitations that may affect its 
performance; for example, derivation from a selected anticoagulated clinical-trial cohort 
that excluded patients with creatinine clearance <30 mL/min and included those with a 
high risk of stroke development, as the latter is contradictory to current 
recommendations to first identify low-risk patients [77]. However, there is still a need 
for further validation of the R2CHADS2 in a real world cohort with full spectrum of 
eGFR [103].  
The new ATRIA risk score might be the newest TE risk stratification scheme proposed. 
This score was derived from the ATRIA cohort and it represents a point-based 
stratification scheme. The new ATRIA TE risk score is calculated by adding 1 point for 
each of the following factors: female sex, diabetes mellitus, congestive heart failure, 
hypertension, proteinuria and renal dysfunction (i.e. eGFR < 45 mL/min/1.73 m2 or 
end-stage renal disease) and by adding 0 to 9 points depending on the specific score 
weighting of patients age according to the presence or absence of prior ischemic stroke 
with a maximum score of 15 points [102]. ATRIA TE risk score looks to be more 
complex than the other scores.  
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Table 1.1: Thromboembolic risk stratification with CHA2DS2-VASc [92] and 
R2CHADS2 [101] scores.  
CHA2DS2-VASc risk factor Score R2CHADS2 risk factor Score  
Congestive heart failure/left ventricular 
dysfunction 
1 Renal dysfunction (i.e. 
creatinine clearance <60 
mL/min) 
2 
Hypertension 1 Congestive heart failure 1 
Age ≥75 years 2 Hypertension 1 
Diabetes mellitus 1 Age ≥75 years 1 
Stroke/transient ischemic attack 2 Diabetes mellitus 1 
Vascular disease (coronary artery 
disease, peripheral arterial disease, or 
aortic plaque) 
1 Stroke/transient  ischemic 
attack 
2 
Age 65–74 years 1   
Sex category (female gender) 1   










Table 1.2: Thromboembolic risk stratification with ATRIA thromboembolic risk score 
[102]. 
ATRIA thromboembolic risk factor Score without prior 
stroke 
Score with prior 
stroke 
Age, years    
≥85 6 9 
75–84 5 7 
65–74 3 7 
<65 0 8 
Female sex  1 1 
Diabetes mellitus 1 1 
Congestive heart failure 1 1 
Hypertension 1 1 
Proteinuria 1 1 
Estimated glomerular filtration rate <45 
mL/min/1.73m2 or end stage renal 
disease 
1 1 








Bleeding risk stratification in patients with non-valvular atrial fibrillation on vitamin 
K antagonists: 
The consequences of major bleeding during oral anticoagulation represent a potential 
fatal hazard of therapy, so we always need to recognize those patients with specific risk 
factors for adverse bleeding events. To some extent, estimation of the bleeding risk 
during AF is far more complex than the estimation of TE risk. Several clinical risk 
models for bleeding risk assessment have been developed to help the decision-making 
process when prescribing VKAs to AF patients [85].  
Currently different clinical guidelines recommend the HAS-BLED [104] (Hypertension 
[uncontrolled: systolic >160 mm Hg]), Abnormal renal function, abnormal liver 
function, Stroke, Bleeding history or predisposition (anemia), Labile international 
normalized ratios, Elderly > 65 years, and Drugs/alcohol concomitantly) risk score for 
bleeding risk assessment in patients with NVAF [77,105]. HAS-BLED is calculated by 
adding 1 point for each of the 9 individual variables it includes [104]. Compared with 
other bleeding risk scores, the superiority of the HAS-BLED score was also 
demonstrated with a stepwise increase in rates of major bleeding with increasing HAS-
BLED score (p < 0.0001) [106]. 
More recently, the ATRIA bleeding risk score was derived from the ATRIA study 
[107]. The ATRIA score is calculated by adding 3 points for anemia; 3 points for eGFR 
< 30 mL/min/1.73m2; 2 points for age ≥75 years; 1 point for prior bleeding, and 1 point 
for diagnosed hypertension [107]. Different studies have demonstrated that HAS-BLED 
score performs better than the ATRIA at predicting major bleeding in NVAF patients 
[108-110]. However, the results obtained by these studies might not be truly 
representative of the real world outpatient practice as some of these studies came from 
clinical trial population or from hospitalized patients [108,110]. Moreover, there is 
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limited information about the comparative performance of both scores at predicting ICH 
which is the most dreadful complication of oral anticoagulation therapy [108,109]. 
Furthermore, the few studies compared both scores in real world practice used 
“modified” versions of the original scores [109] and this brings doubts about the 
validity of their results.  
Table 1.3: Bleeding risk stratification with HAS-BLED [104] and ATRIA [107] scores. 
HAS-BLED risk factor Score ATRIA bleeding risk factor Score  
Hypertension (systolic blood pressure 
>160mm Hg) 
1 Anemia (i.e. Hemoglobin <13 




Abnormal renal and/or liver function 1 or 2 Severe renal disease (estimated 
glomerular filtration rate 
<30 mL/min or dialysis 
dependent) 
3 
Stroke 1 Age ≥75 years 2 
Bleeding tendency or predisposition 1 Prior hemorrhage 1 
Labile international normalized ratios 1 Hypertension 1 
Elderly (e.g. age >65 years, frail 
condition) 
1   
Drugs (e.g. concomitant antiplatelet or 
Nonsteroidal anti-inflammatory drugs) 
or alcohol excess/abuse 
1 or 2   
Maximum score 9  10 
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A new score proposed to predict quality control of anticoagulation with vitamin K 
antagonists: 
 
The peculiar characteristics of VKAs make them difficult to handle. VKAs are 
considered inconvenient drug as they have several limitations mainly due to their 
narrow therapeutic window and variable dose requirement. To maintain the dose of 
VKAs in the therapeutic range, many different factors should be taken into 
consideration like race, dietary vitamin K intake, comorbidities (e.g. liver disease) or 
whether the patient is taking interacting drugs [72]. Nevertheless, maintaining the 
therapeutic dose of VKAs is also partly influenced by genetic polymorphisms [111]. 
However, pharmacogenetics-guided dosing of VKAs has not yet demonstrated the 
ability to decrease the incidence of labile INR, and consequently, to decrease major 
adverse events and to be cost-effective in patients taking VKAs [112]. Really, patients 
in the real world clinical practice tend to be older, with associated comorbidities like 
cardiovascular disease with their polypharmacy regimen, which often result in weak 
adherence and poor quality of anticoagulation expressed as low PINRR or TTR [113]. 
The availability of NOACs have revolutionized the landscape of anticoagulation 
management and greatly increased the interest toward finding an easy clinical tool to 
identify those patients who would do well on VKAs or conversely, to be a good 
candidate for one of the  NOACs. In this regard, Apostolakis et al [114], proposed the 
SAME-TT2R2 score [Sex, Age (< 60 years), Medical history (more than two of the 
following: hypertension, diabetes, coronary artery disease/myocardial infarction, 
peripheral arterial disease, congestive heart failure, previous stroke, pulmonary disease, 
hepatic or renal disease), Treatment (interacting drugs, e.g. amiodarone for rhythm 
control) (all 1 point), as well as Tobacco use (2 points) and Race (non-Caucasian; 2 
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points)]. This simple clinical score might help decision making by identifying those AF 
patients that would probably do well on VKAs with a high PINNR or TTR. However, 
the SAMe-TT2R2 score still need further validation in real world cohorts before being a 
reliable tool.  
Table 1.4: Quality of anticoagulation control assessment with SAMe-TT2R2 score 
[114]. 
SAMe-TT2R2 risk  factor Score  
Sex (i.e. female) 1 
Age <60 years 1 
Medical history (more than two of the following: hypertension, diabetes, 
coronary artery disease/myocardial infarction, peripheral arterial disease, 
congestive heart failure, previous stroke, pulmonary disease, hepatic or 
renal disease) 
1 
Treatment with interacting drugs (e.g. amiodarone) 1 
Tobacco use 2 
Race (nonwhite) 2 









The relevance of renal dysfunction in non-valvular atrial fibrillation patients on 
vitamin K antagonists (a special and complex concern): 
  
The frequency of AF in patients with end-stage renal failure is 10 to 20 fold higher than 
that of the general population, although significant variability in prevalence exists 
between the studies, ranging from 7% to 27% [115-117]. Moreover, chronic kidney 
disease (CKD) is a common comorbidity among AF patients. In Spain the prevalence of 
renal dysfunction in patients with AF estimated to be 31.6% [118]. CKD results in 
complex pathophysiological changes, involving both hypo- and hypercoagulability 
[119]. An intimate relationship between CKD and oral anticoagulant related 
hemorrhagic events is well established. As a result, severe CKD is a predictor in most 
oral anticoagulant related bleeding risk estimation tools [104,107]. On the other hand, 
patients with AF and advanced CKD have higher risk of TE events compared with AF 
patients and normal renal function [120,121].  
All these data when taken together indicate that accurate assessment of renal function is 
of paramount importance as it will help inform the decision making process regarding 
the optimal management of patients with AF. Currently, it is recommended to estimate 
renal function by means of eGFR using the prediction equations instead of serum 
creatinine [122]. 
The two most commonly used equations to estimate GFR were the MDRD-4 Study 
[123] and the Cockcroft-Gault equation [124]. The MDRD-4 equation was re-expressed 
and revalidated to be used in the current era of standardized serum creatinine assay, 
whereas the Cockcroft-Gault equation was not updated, and its use is not recommended 
currently [125]. More recently, a new equation, the CKD-EPI equation [126], has been 
proposed as an alternative equation to replace the widely used re-expressed MDRD-4 
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formula in routine clinical practice. Although, the new CKD-EPI outperformed the re-
expressed MDRD-4 formula at estimating the true renal function in several studies 
[127-129].  However, it is still unknown if the better estimates from the new CKD-EPI 
would be translated into better risk prediction in the particular context of patients with 
NVAF, as very few percentage of patients in the derivation cohort of the new CKD-EPI 
formula were having AF [126]. 
 
 








Current challenges in the management of non-valvular atrial 






















As AF becomes more and more prevalent, there is a substantial interest to address the 
challenges that prevent optimal management of this condition. 
 
Global Challenges in the real world to maintain high quality control of VKAs: 
Over the last five decades, VKAs have been the mainstay of oral anticoagulation 
treatment and multiple clinical trials had shown that well-controlled, dose-adjusted 
VKAs are a safe and effective therapy to reduce the risk of TE event in AF patients. 
However, the practical difficulties in maintaining the therapeutic INR, understandably 
raise many concerns that the efficacy and safety achieved with VKAs in clinical trials 
might not reflect what can be observed in daily clinical practice. Clinical trials monitor 
patients very closely, more than might be practical or possible in routine clinical 
practice. Moreover, to meet trial design and ethical requirements, clinical trials often 
exclude patients at high risk of bleeding while also recruiting relatively few elderly 
patients [130,131]. 
VKAs have a narrow therapeutic range and they interact with many common foods and 
medicines. In this regard, VKAs require close monitoring and frequent dose adjustments 
to ensure that patients receive a dose that consistently maintains a reduced risk of stroke 
without increasing the risk of bleeding. Really, maintaining therapeutic range in patients 
treated with VKAs has always been challenging and the potential consequences of 
deviating from the therapeutic range can result in a devastating event. Several indices of 
anticoagulation quality have been proposed, TTR and PINRR being the most widely 
used [132]. Both major bleeding and mortality rates have been reported to be 




In a recent meta-analysis of AF studies performed worldwide between 1990 and 2013 
they found that just only 61% of their TTR and only 56% of their PINRR were in 
therapeutic range [132]. Moreover, a recently published study looked at the length of 
time patients spend in the target range of VKAs in France, Germany, Italy and the 
United Kingdom. They found that more than half the patients evaluated in France 
(52%), Germany (56 %) and Italy (54 %) had poorly controlled treatment (defined as 
spending less than 70 per cent of time within the target therapeutic range). In the United 
Kingdom this proportion was just 35%, and this difference may be attributable to the 
use of specialized clinics for monitoring treatment, where patients were more closely 
followed and the dose of VKAs was adapted in a more responsive manner than was the 
case in the other countries [134]. 
It is clearly recognized that it’s not simply prescribing VKAs as very close attention to 
the quality of anticoagulation control is necessary. Moreover, it is not easy to achieve a 
high TTR/PINRR because of the inconvenience of regular anticoagulation monitoring 
and the various food/drug restrictions associated with the VKAs. 
More recently, we have had the NOACs [135] available, which offer efficacy, safety 
and relative convenience compared to the VKAs, for TE prevention in AF.  When a 
patient is first started on a VKA, the inception period is often associated with poor 
TTR/PINRR, and an excess of TE event has been noted in various studies and this 
discourages the use of VKAs stress test in VKAs naïve patients [136,137].  
A major challenge therefore is to easily identify those AF patients who are less likely to 
do well on  VKAs (with an expected poor TTR/PINRR) who may be best switched to  
NOACs, rather than being exposed to suboptimal TTRs and inadequate 




Ischemic stroke………………………………………..Hemorrhagic stroke  
Figure 2.1: The estimation of risk-benefit ratio of vitamin K antagonists is a continuous 
challenge. 
 
A continuous challenge to refine TE risk scores and to define truly low risk patients: 
Medicine might be considered as a science of uncertainty and an art of probability 
[138], and this is especially true in the decision making process to prevent stroke in 
patients with AF. In clinical practice, the decision to initiate anticoagulation in patients 
with AF starts with an attempt to quantify the patient’s stroke risk. It has been 
recognized for some time that TE risk in patients with AF depends less on the 
“quantity” or “severity” of their AF and more on other clinical characteristics. 
Epidemiological and observational studies continue to analyze these clinical variables 
with the aim to yield a number of risk stratification schemes to help guide 
anticoagulation decisions. 
CHADS2 score was validated and conceived in the year of 2001 with the aim of 
identifying patients at high risk of TE events [89].  However, patients at low risk 
according to CHADS2 score continued to have significant annual stroke rate (i.e. 2%) 
[93,139],  this yielded a great interest to investigate the significance of other risk factors 
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not included in the CHADS2 score and, in turn, has led to a shift in the clinical paradigm 
with a new aim to identify “truly low risk” patients using CHA2DS2-VASc score [92]. 
The advantages of the CHA2DS2-VASc score were clearly demonstrated in a 
retrospective analysis performed in the Danish nationwide cohort study, which involved 
patients with CHADS2 score 0 (i.e. low-risk patients). When their stroke risk was sub-
stratified according to the CHA2DS2-VASc score, those with a CHADS2 score of 0 had 
stroke rates ranging from 0.8% per year to 3.2% per year [93]. However the ability of 
the of the CHA2DS2-VASc score to define truly low risk patients might be still in 
question as it can be concluded from a recently published large nationwide cohort from 
the real world in which low risk patients according to the CHA2DS2-VASc were having 
an annual stroke rate [100] that might be considered a significant risk which may 
deserve anticoagulation with the NOACs [140]. This puts a continuous challenge to 
truly identify low risk patients in the real world practice and points to the need for 
directing more efforts towards improvement of the performance of the current TE risk 
scores and to define more new risk factors.                                                                                                     
In this regard, two new TE risk scores (i.e. R2CHADS2 [101], and the ATRIA TE risk 
scores [102]) include new TE risk factors in their schemes (i.e. renal dysfunction and 
proteinuria) and where proposed to improve the ability to predict TE event.                                                                
Renal dysfunction is still one of the current challenges as it is well known that patients 
with renal dysfunction are at an increased risk of TE event and of (i.e. if they are 
anticoagulated) bleeding [120,121]. Giving the increased prevalence of aging 
population, hypertension, heart failure and diabetes, the associated increased incidence 
of renal dysfunction becomes a global challenge. This challenge extends to the dilemma 
of anticoagulation for patients with AF [119]. Therefore, it has been proposed that renal 
dysfunction should be added to the widely used stroke risk stratification schemes for AF 
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(i.e. CHADS2 and CHA2DS2-VASc), as this will effectively lower the threshold for 
anticoagulant treatment in these patients. On the other hand, some have argued that 
renal dysfunction is a strong risk factor for bleeding complications in conjunction with 
anticoagulation, and thus, renal disease rather should invoke caution and a raised 
threshold for initiating anticoagulation [119, 120,121]. 
Deserve to mention here, the special challenge of how to avoid further TE event in 
anticoagulated patients.  It is well known from different studies that there is annual TE 
rate of about 1-2% despite anticoagulation. This group of patients at high risk represents 
a real challenge as the identification of patients who remain at high risk of TE event 
despite anticoagulation may affect treatment strategies of clinical practice [94,120].  
Really, the serious and continuous challenge which is facing the cardiologists in the 
daily clinical practice is the fact that the majority of patients with AF are often elderly 
and have associated comorbidities like hypertension and prior stroke which are also 
considered bleeding risk factors and this means that the same patient could have 
moderate to high risk of both stroke and bleeding at the same time [85]. 
However, in the real world practice, prescribing anticoagulant agents for patients with 
AF is ultimately a clinical decision to be made between the physician and the patient.  
Risk stratification schemes could aid in our clinical decision making only if we use 











Future considerations in the dilemma of non-valvular atrial fibrillation 























To prescribe VKAs or NOACs, how will it be a simple decision for cardiologists? 
Proper prevention of TE event with oral anticoagulants is key to modern management of 
AF patients [77]. Now and for many years, VKAs have been the most common oral 
anticoagulants used in many countries, despite our recognition that it’s not simply 
prescribing VKAs as very close attention to quality of anticoagulation control is 
necessary [72]. This became more pronounced as a TTR of >70% is recommended, to 
maximize the efficacy and safety of the VKAs [72,76].  
It is clear that VKAs continue to be inconvenient drugs as they have significant inter- 
and intra-patient variability, partly from diet and drug interactions, thus necessitating 
regular and continuous INR monitoring [72]. These concerns have led to the 
introduction of the NOACs, which have more efficacy, safety and convenience 
compared to the VKAs [135]. Thus, poorly controlled VKAs therapy patients would 
beneficiate from switching to anticoagulant therapy with one of the NOACs, especially 
if they were VKA experienced patients. But the critical question now is what about 
decision making in anticoagulation naïve patients to start with VKAs or NOACs? 
Due to the high cost of the NOACs, many healthcare systems mandate a trial of VKAs 
(i.e. VKAs stress test ) for the initial 6 months, to determine whether a patient can do 
well on a VKAs and only if the TTR/PINRR is suboptimal (e.g. <60%) then a NOACs 
can be prescribed. But the fact that when a patient is first started on a VKA, the 
inception period is often associated with poor TTR/PINRR, may make the VKAs stress 
test a hazard approach as an excess of TE event has been noted in various studies 
[136,137].  
Much of the recent and current efforts are therefore directed to easily identify those AF 
patients who are less likely to do well on VKAs (i.e. with a poor TTR/PINRR) who may 
be best switched to NOACs, rather than being exposed to suboptimal TTR/PINRR that 
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could expose the patient to fatal and disabling major bleeding or TE event and rather 
than using guesswork (or budget considerations) to decide between VKAs or NOACs in 
a newly diagnosed anticoagulation naïve patient.  It is appreciated that rather than a 
‘trial of VKAs’ for every patient, the decision-making for cardiologists could be easier, 
with the availability of a simple easy clinical tool to identify those patient who would do 
well on VKAs ( i.e. with high TTR/PINRR) or conversely, who would on probability 
are likely to have low TTR/PINRR.  
Although, more recently a simple clinical score (i.e. SAMeTT2R2) [114], has been 
proposed to help decision making by identifying those AF patients that would probably 
do well on VKAs with a high average TTR/PINRR. However, more future efforts 
should be directed to further validation and improvement of the performance of this 
score in contemporary real world populations of AF patients who are VKAs naïve 








Figure 3.1: A proposed plan for using the SAMe-TT2R2 score and to help the decision 
making regarding the anticoagulation choice in naïve patients with NVAF [141]. 
NOAC: new oral anticoagulant; OAC: oral anticoagulation; SAMe-TT2R2: Sex female, 
Age < 60 years, Medical history [more than two comorbidities], Treatment [interacting 
drug, e.g. Amiodarone], Tobacco use [doubled], and Race [doubled]); TTR: time within 
therapeutic range; VKA: vitamin K antagonist. 
 
In the future there is a need for continued improvement in patient risk stratification and 
personalization of care: 
There is potential for improvement in the extent to which AF management is directed to 
the needs of individual patient, in terms of both biomedical and social factors, by 
expanding and making use of the evidence based on biomarkers, genomic factors and 
outcomes for a range of patients and therapies. One area that could be further developed 
is TE risk stratification, where our understanding of patient who should be prescribed 
anticoagulants for prevention of AF related TE event could be further refined.  A better 
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understanding of that risk may make it possible to reduce the number of patients 
receiving anticoagulation in the future.  In terms of social factors, there is also scope for 
patients' preference to play a larger role in the future in clinical decisions about which 
management options are most appropriate for them. Adapting management to patient 
needs and preferences can help improve compliance. For example, in terms of 
preferences for VKAs versus NOACs for anticoagulation, some patients may prefer the 
regular interaction they receive through monitoring when on VKAs. On the other hand, 
other patients, such as those who work full-time, may prefer the reduced burden 
associated with NOACs (the lack of a need for monitoring and fewer restrictions related 
to food and drug interactions).  Ongoing clinical trials are currently gathering evidence 
to enable a better understanding of biomarkers, risk factors and outcomes in patient 
groups that have been less well studied. Biomarkers based risk scores for predicting TE 
event in AF could be available in the future. An example of these biomarkers is the 
natriuretic peptides as the previous studies described elevated levels of natriuretic 
peptides in patients with AF as compared to matched controls in sinus rhythm 
[142,143]. Moreover, it was thereafter reported that levels of natriuretic peptides fall 
rapidly following restoration of sinus rhythm [144]. Furthermore, a community based 
cohort study on elderly adults demonstrated that elevated natriuretic peptides levels 
predicts an increased risk for development of AF independent of other risk factors 
including echocardiographic parameters [145,146]. The future could carry new TE risk 
scores which incorporate biomarkers beside the clinical variables as such scores may 





Figure 3.2: In the future every patient with atrial fibrillation may have his own 













Evaluation of SAMe-TT2R2 risk score for predicting the quality of 
anticoagulation control in a real-world cohort of patients with non-
valvular atrial fibrillation on vitamin-K antagonists 
 




























Comparison between CHA2DS2-VASc and the new R2CHADS2 and 
ATRIA scores at predicting thromboembolic event in non-
anticoagulated and anticoagulated patients with non-valvular atrial 
fibrillation 
 
































Comparative evaluation of HAS-BLED and ATRIA scores by 
investigating the full potential of their bleeding prediction schemes in 
non-valvular atrial fibrillation patients on vitamin-K antagonists 
 

























Renal function assessment in atrial fibrillation: Usefulness of chronic 
kidney disease epidemiology collaboration vs re-expressed 4 variable 
modification of diet in renal disease 
 































































A way of improving the ability to predict the quality control of vitamin K antagonists 
in naïve patients with non-valvular atrial fibrillation: 
In the real world clinical practice and in the dilemma of anticoagulation in NVAF, 
cardiologists are still facing substantial difficulties in dealing with anticoagulants naïve 
NVAF patients when different critical decisions need to be carried out quickly 
regarding to start or not the anticoagulation?; with which agent to start,  one of VKAs or 
one of NOACs?. Usually, the precautions of anticoagulation derived from patients 
clinical variables make the decision to start anticoagulation in those patients greatly 
challenging. Moreover, patients with NVAF, are frequently old, with several 
comorbidities (e.g. cardiovascular disease and/or renal dysfunction), and complex 
pharmacotherapy which can include antiplatelet therapy, all these factors add great 
obstacles to the decision making process, to the plan of follow up and to the accurate 
estimation of the thromboembolic and hemorrhagic risk. 
In the real world practice, maintaining the therapeutic range in patients treated with 
VKAs had always been challenging whilst the potential consequences of deviating from 
the optimal control of VKAs are deleterious in patients with NVAF, given the increased 
risk for thromboembolic and bleeding events [73-76].  
Various clinical decision making tools have been developed to help decision making in 
the management of patients with NVAF. In 2013, the new score - SAMe-TT2R2 - was 
proposed to help identify those patients who were likely to have a propensity to poor 
INR control. This simple score based on clinical features may help identify those AF 
patients who would do well on VKAs (i.e. SAMe-TT2R2 score = 0–1), or conversely, 
those who might require additional interventions to achieve acceptable anticoagulation 
control (i.e. SAMe-TT2R2 score ≥2) [114]. This score was derived from a trial cohort 
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and thus independent validation in ‘real-world’ AF cohorts would be needed. We 
performed a retrospective analysis of a cohort of outpatients with NVAF recently (i.e. 
not who were on VKAs for long time and for a better assessment of SAMe-TT2R2 
score) on VKAs and found that SAMe-TT2R2 score could indeed represent a useful 
clinical tool to identify poor quality of anticoagulation control with VKAs. The 
predictive ability of SAMe-TT2R2 is acceptable for identifying poor PINRR and its 
ability has been improved when integrated with other clinical characteristics. Really, 
our research demonstrates that SAMe-TT2R2 can be used as a reliable score to refine the 
clinician judgment regarding the correct identification of patients who would have high 
quality of anticoagulation control with VKAs and distinguish them from those less 
likely to do well on VKAs for whom close follow up or the use of NOACs should be 
proposed as an alternative therapeutic option aiming to avoid the excess risk of stroke 
and bleeding. For this purpose, SAMe-TT2R2 may represent a good clinical tool which 
can facilitate the physician decision making process to optimize the oral anticoagulation 
management. Moreover, our study gives more attention to cardinal risk factors such as 
heart failure, eGFR less than 30 mL/min/1.73 m2, diabetes mellitus and history of 
malignancy which should seriously be taken into account by the clinicians when they 
prescribe VKAs in daily clinical practice as these risk factors are common in patients 






Insights at assessment of thromboembolic and bleeding risk in patients with non-
valvular atrial fibrillation: 
Although, the most commonly used risk score for the prediction of TE event is the 
CHA2DS2-VASc [92]. However, the continuous refinement of risk scores is a never 
ending process, and as such two new TE risk scores (i.e. R2CHADS2 [101] and ATRIA 
[102]) has been proposed for this purpose as they -in their own derivation- 
outperformed the CHA2DS2-VASc. Really, these recently proposed scores contain new 
risk factors in their schemes (e.g. renal dysfunction) which were not included in the 
most popular CHA2DS2-VASc score. One can assume that the integration of new risk 
factors might qualify them to more accurately capture the risk of suffering a TE event. 
However, limited information is available about the comparative abilities of these three 
risk scores in independent real world cohorts of patients with NVAF.  Our study 
compares these three contemporary TE risk scores in non-anticoagulated and 
anticoagulated different real world cohorts of patients with NVAF, and shows that 
despite similar association and discrimination of the three scores in the anticoagulated 
cohort. However, CHA2DS2-VASc was the only score to show significant association in 
terms of hazard ratio at predicting TE events in the non-anticoagulated cohort. Thus, our 
research demonstrates clearly that CHA2DS2-VASc is still the best score to be used by 
the cardiologists in the real world practice at predicting TE event and at defining truly 
low risk patient. One of the interesting findings of our research shows that those patients 
in the high risk category (i.e. with high points of risk) according to CHA2DS2-VASc 
and the R2CHADS2 are still at high risk of developing TE event despite being on 
uninterrupted VKAs. This point would need further research, as the identification of 
patients who remain at high risk of TE event despite anticoagulation could be of great 
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value and highly appreciated by the physicians in daily clinical practice as by this 
approach the clinicians might identify early these patients who need specific treatment 
strategy with more frequent follow up visits and  more efforts directed to improve the 
quality control  of anticoagulation and to achieve the best management of their partially 
modifiable risk factors like hypertension, diabetes and heart failure. Really, several 
reports demonstrated that the risk of major adverse event (i.e. TE event and major 
bleeding) is greatest in the first few months after starting VKAs, this might indicate the 
importance of risk assessment for those patients who are recently on VKAs [80,148]. 
Oral anticoagulants carry the risk of major bleeding events among which is ICH that 
constitutes the most dreadful complication of oral anticoagulation. In real world 
practice, clinicians highly appreciate tools which are proposed to predict the occurrence 
of major bleeding event especially ICH as by this they can minimize the chance of 
suffering from these catastrophic events. In our study, the HAS-BLED [104] score 
provides a more useful tool than ATRIA [107] for prediction of major bleeding 
particularly ICH, and the results of our analysis increase the confidence to use HAS-
BLED score in the real world practice. Moreover, our study provides new insight on the 
importance of certain comorbidities like diabetes mellitus and chronic obstructive 
pulmonary disease which were identified as independent predictors of major bleeding 
and the need to take these new risk factors into consideration when prescribing VKAs 
as these factors when taken into account beside the HAS-BLED score might improve 
the ability of estimating major bleeding risk. Furthermore, poor quality of 
anticoagulation control with VKAs (i.e. labile INR) is a significant predictor of major 
bleeding in our population of patients with NVAF recently on VKAs. This may point to 
the critical need of having a valid clinical tool to predict the quality of anticoagulation 
control before prescribing VKAs.  
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Advance in renal function assessment in patients with non-valvular atrial fibrillation: 
In daily clinical practice, when dealing with patients having NVAF, renal function 
assessment is frequently requested by the cardiologists to optimize the management 
plan, mainly because renal dysfunction is associated with TE and bleeding event, and 
can have negative effects on the pharmacotherapy regime. Thus, accurate renal function 
assessment could be of great help in daily practice. The re-expressed MDRD-4 [125] 
and CKD-EPI [126] are the two equations available to be used in the current era of 
standardized serum creatinine. However, little data is available about their values in the 
population of patients with NVAF. Our study tries to uncover this area of uncertainty 
with the goal to define the best clinically justifiable and reliable equation to be used in 
the context of NVAF. Although, the analysis of our study demonstrates that eGFR 
values derived from both equations have the same prognostic impact. However, the 
results of our study show that the new CKD-EPI formula has a reasonable ability to 
reduce the rate of patients with renal dysfunction. When taken together, these results 
could be highly appreciated by clinicians in real world practice which usually needs 
close attention to status of renal function to reach optimal management, and for safer 
use of renally excreted medications, in patients with NVAF. Thus, our study increases 
the confidence to use CKD-EPI by the laboratories and cardiologists in the particular 
context of NVAF.  Our analysis demonstrates that severe renal dysfunction (i.e. eGFR 
less than 30 mL/min/1.73 m2) is significantly associated with poor quality of VKAs and 
TE event in patients with NVAF on VKAs, this may reflect the need for more follow-up 





Cardiovascular disease and non-valvular atrial fibrillation, a way to improve the 
outcome: 
Our study demonstrates high prevalence of cardiovascular disease among 
anticoagulated patients with NVAF mainly hypertension, heart failure and coronary 
artery disease as it showed that their prevalence was 74.4%, 37.7% and 13.9%, 
respectively. Moreover, our analysis shows that heart failure is strongly associated with 
poor quality control of VKAs and hence more adverse outcomes. The combination of 
heart failure and AF constitutes an epidemic in modern cardiology. Furthermore, the 
analysis reflects that the presence of multiple cardiovascular diseases (i.e. more than 
two medical comorbidities according to SAMe-TT2R2 score) is strongly associated with 
poor quality control of anticoagulation with VKAs. All these findings reflect the critical 
need to put more efforts toward optimal management of all associated cardiovascular 
morbidities and risk factors in patients with NVAF in order to improve the outcomes 
and not to treat NVAF as a separate entity. Further studies are needed to clarify this 
dilemma. On the other hand, among cardiovascular drugs, amiodarone shows significant 
association with poor quality control of VKAs, and this may point to the need to give 






Figure 8.1: Targeting the optimal therapy in the setting of non-valvular atrial 
fibrillation, requires balancing considerations of the patient risk scores. CHA2DS2-
VASc: congestive heart failure, hypertension, age ≥75, diabetes mellitus, stroke, 
vascular disease, female sex category; HAS-BLED: uncontrolled Hypertension: systolic 
>160 mm Hg, Abnormal renal/liver function, Stroke, Bleeding history or predisposition, 
Labile international normalized ratio, Elderly >65 years, Drugs/alcohol concomitantly; 
NOAC; new oral anticoagulant; NVAF; non-valvular atrial fibrillation; SAMe-TT2R2: 
Sex female, Age < 60 years, Medical history [more than two comorbidities], Treatment 
[interacting drug, e.g. Amiodarone], Tobacco use [doubled], and Race [doubled]); 
































Although specific conclusions are detailed in each chapter, those presented below can 
reflect the overall objectives of this research. 
 
In relation to objective 1: 
 
1- The anticoagulation quality control of VKAs in Galician patients with NVAF is 
still below the optimal level as the mean PINRR in this real world cohort was 
58% ±18 indicating the need for more efforts toward the improvement of the 
quality control of VKAs in our population. 
2- In patients with NVAF recently on VKAs, the SAMe-TT2R2 score constitutes a 
user-friendly tool for predicting the quality of anticoagulation control with 
VKAs. Moreover, the SAMe-TT2R2 score successfully predicts mortality and 
the composite outcome of major bleeding, TE complications, and mortality in 
our population. 
3- Cardiovascular diseases are highly prevalent in patients with NVAF. Heart 
failure deserves great attention as it commonly accompanied AF and 
demonstrated a strong association with poor quality control of VKAs. Moreover, 
among cardiovascular drugs, amiodarone shows significant association with 
poor quality control of VKAs. 
4- The performance of SAMe-TT2R2 could be improved by taking into account 
other cardinal risk factors related to poor INR control like eGFR less than 30 
mL/min/1.73 m2, history of malignancy, diabetes mellitus, heart failure and 





In relation to objective 2:  
 
1- The annual rate of TE event is noticeable (i.e. about 2%) in a real world cohort 
of Galician patients with NVAF despite being on uninterrupted anticoagulation 
with VKAs. The CHA2DS2-VASc, R2CHADS2 and ATRIA TE risk scores show 
significant association at predicting TE event in these patients. This finding sets 
an alarm for further research to define this category of patients as the 
management plan for them could be different and with intensive follow up visits 
toward minimizing their TE risk. 
2- The CHA2DS2-VASc demonstrates better association with TE event than 
R2CHADS2 or ATRIA TE scores in non-anticoagulated patients with NVAF, 
and represents a more accurate clinical tool for TE risk stratification in these 
patients.  
3- Regarding the identification of patients with low TE risk, the CHA2DS2-VASc 
and the R2CHADS2 scores accurately identify patients at truly low risk of 
developing future TE events while the new ATRIA score fails to show similar 









In relation to objective 3:  
 
1- The annual rate of major bleeding event is nearly 3.3% in a real world cohort of 
Galician patients with NVAF recently on VKAs. The HAS-BLED bleeding risk 
score demonstrates better performance than the ATRIA bleeding score 
especially in prediction of the most catastrophic ICH event in our population. 
Our study encourages the use of HAS-BLED score in the management of 
patients with NVAF in the daily clinical practice. 
2- Poor quality of anticoagulation control with VKAs (i.e. labile INR) is a 
significant predictor of major bleeding in our population of patients with NVAF 
recently on VKAs. This may indicate the importance of having proper risk 
assessment tools to predict the quality of anticoagulation control before 
prescribing VKAs. 
3- The analysis highlights diabetes mellitus and chronic obstructive pulmonary 
disease as strong predictors of major bleeding which might be useful to be taken 
into account when estimating the bleeding risk in patients with NVAF before 










In relation to objective 4: 
 
1- Renal dysfunction is strongly associated with all cause mortality and shows a 
tendency to predict major bleeding event in patients with NVAF on VKAs. 
Moreover, the analysis indicates that patients with NVAF and eGFR less than 30 
mL/min/1.73 m2 may be at high risk of having poor quality control of VKAs and 
major adverse events (i.e. TE event, mortality) compared to those with NVAF 
and normal renal function. 
2- Renal dysfunction reflected by GFR estimates either from the re-expressed 
MDRD-4 or the new CKD-EPI equations is an independent predictor of the 
composite endpoint (i.e. major bleeding, TE complications, or death) and all 
cause mortality. In this regard, both formulas show similar prognostic impacts 
regarding the prediction of composite endpoint, major bleeding, TE events and 
all cause mortality.  
3- The analysis might indicate that the use of the new CKD-EPI equation to 
estimate GFR can reduce the prevalence of patients with renal dysfunction 
compared with the re-expressed MDRD-4 equation, in a real world cohort of 
patients with NVAF.  
4- The findings indicate that the most widespread adoption of the new CKD-EPI 
instead of the re-expressed MDRD-4 may result in modifying the overall 
































Está bien establecido que la fibrilación auricular (FA) aumenta unas 5 veces el riesgo de 
ictus isquémico. Los antagonistas de vitamina K (AVK) continúan siendo los 
anticoagulantes orales más ampliamente usados en los pacientes con FA no valvular 
(FANV), y son considerados muy efectivos para la prevención de complicaciones 
tromeboembólicas (TE) en esos pacientes. Sin embrago, optimizar el beneficio 
terapéutico en el uso de los AVK en la práctica clínica, siguen siendo el principal reto 
debido a lo impredecible de la respuesta anticoagulante. 
La asociación entre la mala calidad de los controles del international normalized ratio 
(INR) y el aumento tanto de la tasa de hemorragias serias como de ictus, está bien 
establecida. 
El tiempo en rango terapéutico (TRT) o el porcentaje en rango terapéutico de los 
controles del INR (PRINR), son metidos usados medir la calidad de los controles de 
anticoagulación con los AVK. 
En la práctica clínica diaria, los registros de los valores de INR son el mejor indicador 
de la calidad de anticoagulación in pacientes tratados durante largo periodo de tiempo 
con AVK. En contraste, en los pacientes sin tratamiento previo con AVK o aquellos con 
inicio reciente de AVK, existe un interés creciente en encontrar una herramienta que 
pueda ayudar a predecir de antemano si esos pacientes presentarán o no una adecuada 
respuesta terapéutica una vez prescrito un AVK. 
Por otra parte, con la disponibilidad de los nuevos anticoagulantes orales (NACO), el 
manejo de la anticoagulación en FANV se ha revolucionado ya que estos nuevos 
fármacos son más seguros que los AVK. De este modo, hay una fuerte necesidad de 
caracterizar los pacientes con FANV con indicación de anticoagulación pero que 
podrían tener pobre calidad de respuesta anticoagulantes con los AVK, por lo cual 
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serían candidatos adecuados para recibir los NACO con el fin de evitar complicaciones 
hemorrágicas graves, así como complicaciones isquémicas. 
El objetivo de nuestro estudio fue evaluar el riesgo de intermedios (es decir, controles 
pobres de INR) y los eventos adversos en pacientes contemporáneos con FANV 
recientemente tratados con AVK. Por otra parte, se evalúan los predictores de presentar 
eventos adversos en estos pacientes, y evaluar la validez de los scores de riesgo 
contemporáneos desarrolladas y recomendadas para su uso en el contexto de FANV. 
Retrospectivamente, se identificaron todos los pacientes consecutivos de ≥ 18 años de 
edad con un diagnóstico confirmado de la FA en AVK, asistiendo a las consultas de 
cardiología ambulatoria en un hospital de tercer nivel entre enero de 2011 y febrero de 
2013.  
Sólo los pacientes que cumplían los siguientes criterios se incluyeron en el estudio: 
pacientes con FA permanente o paroxística recientemente tratados con AVK (es decir, 
no más de 8 meses transcurridos desde el inicio del AVK), y que tienen visitas regulares 
para medidas de INR. 
Se excluyeron los pacientes con prótesis valvular, enfermedad cardíacas reumáticas,  
cáncer activo, demencia y/o interrupción de los AVK. Los pacientes fueron seguidos 
hasta 1 año después de la inclusión en este estudio o hasta el desarrollo de hemorragia 
grave, complicaciones TE, o la muerte.  
En total, se incluyó a 911 pacientes en la cohorte anticoagulada. Por otra parte, se 
incluyeron 154 pacientes consecutivos con FANV que no recibían ningún tratamiento 
anticoagulante. 
 
La historia clínica se recogió de forma detallada para cada paciente y las características 
clínicas basales, junto con la información sobre eventos durante el seguimiento. 
103 
 
- El control de calidad de la anticoagulación con AVK en pacientes gallegos con FANV 
es aún por debajo del nivel óptimo como el PRINR en esta cohorte del mundo real fue 
58% indicando la necesidad de más esfuerzos hacia la mejora del control de calidad de 
la anticoagulación con AVK en nuestra población. 
- Las enfermedades cardiovasculares son muy prevalentes en pacientes con FANV y la 
insuficiencia cardíaca merece gran atención, ya que comúnmente acompaña AF, y 
demostró una fuerte asociación con el mal control de la calidad de AVK, y los 
resultados adversos. Por otra parte, entre los fármacos cardiovasculares, la amiodarona 
se asocia con un mal control de calidad de anticoagulación con AVK. 
- El score SAMe-T2R2 constituye una herramienta fácil de usar para la predicción de la 
calidad del control de la anticoagulación con AVK. El rendimiento de SAMe-TT2R2 
podría mejorarse teniendo en cuenta otros factores de riesgo relacionados con un mal 
control de INR como: disfunción renal, antecedentes de cáncer, diabetes mellitus, 
insuficiencia cardíaca y el abuso del alcohol. Estos factores deben tenerse en cuenta 
antes de prescribir AVK. 
- La tasa de evento TE a pesar de la anticoagulación es notable (aproximadamente de 
2%). En cuanto a la identificación de los pacientes con bajo riesgo de TE, los scores  
CHA2DS2-VASc y R2-CHADS2 identifican con mayor precisión a los pacientes en 
verdadero bajo riesgo de desarrollar futuros eventos TE, mientras que el score ATRIA 
no alcanzó habilidad similar. 
- La incidencia de hemorragias graves fue del 3,3%. La puntuación de riesgo HAS-
BLED sangrado demuestra mejor rendimiento que el ATRIA sangrado puntuación 
especialmente en la predicción de la hemorragia intracraneal, en una cohorte 
contemporánea de pacientes gallegos afectos de FANV y anticoagulados con AVK. 
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- Nuestro estudio alienta el uso de HAS-BLED, en el manejo de pacientes con FANV 
en la práctica clínica diaria. Además, la diabetes mellitus y la enfermedad pulmonar 
obstructiva crónica son fuertes predictores de hemorragia mayor, que deben tenerse en 
cuenta en la estimación del riesgo de hemorragia en pacientes con FANV antes de 
prescribir AVK. Son necesarios más estudios en esta área. 
- La disfunción renal estimada por la tasa de filtración glomerular, ya sea calculado por 
la ecuación MDRD-4 re-expresada o la fórmula CKD-EPI, es un predictor 
independiente de hemorragia grave, TE o muerte, así como de mortalidad por cualquier 
causa. En este sentido, ambas fórmulas muestran impactos pronósticos similares en 
cuanto a la predicción de la variable combinada (hemorragia grave, TE y mortalidad por 
cualquier causa). Sin embargo, en este estudio se encontró que el uso de la nueva 
ecuación CKD-EPI reduce la prevalencia de pacientes con disfunción renal en 
comparación con la ecuación MDRD-4 re-expresada. Todo esto podría indicar que la 
adopción más generalizada de la nueva CKD-EPI en lugar de la MDRD-4 re-expresada 
puede dar lugar a la modificación del manejo general de los pacientes con FANV, en 
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